Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$55.45 USD

55.45
10,808,187

+1.13 (2.08%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $55.46 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

Celldex's Immuno-Oncology Pipeline Continues to Impress

On May 25, we issued an updated research report on Hampton, NJ-based Celldex Therapeutics, Inc. (CLDX).

    Arpita Dutt headshot

    Pharma Stock Roundup: Label Expansion for Merck Drug, Aerie Up On Eye Data

    Merck (MRK) got another approval for Keytruda while Aerie shot up on positive data.

      Bristol-Myers' Opdivo Gets Priority Review for Liver Cancer

      Bristol-Myers Squibb Company (BMY) announced that the FDA has accepted and granted a priority review designation to the supplemental Biologics License Application for the label expansion of Opdivo to patients with hepatocellular carcinoma (HCC).

        Merck KGaA (MKGAF) Q1 Earnings Fall Y/Y, Revenues Increase

        Merck KGaA (MKGAF) reported first-quarter 2017 earnings of $1.28 per American Depositary Share, 14.7% lower than the year-ago figure of $1.50.

          Arpita Dutt headshot

          Pharma Stock Roundup: J&J's Pharma Pipeline Update, Shire's HAE Data & More

          This week, industry bellwether J&J (JNJ) provided a look at its pharma pipeline while Shire was up on HAE data.

            Sheraz Mian headshot

            New Research Reports for Britol-Myers, Pricline & Phillips 66

            Today's Research Daily features new research reports on 16 major stocks, including Bristol-Myers (BMY), Priceline (PCLN) and Phillips 66 (PSX).

              Incyte (INCY) Announces Positive Data on Enzyme Inhibitor

              Incyte Corporation (INCY) recently announced that new data was published from the ongoing trial, ECHO-202 online by the American Society of Clinical Oncology (ASCO).

                Biogen (BIIB) Buys Stroke Candidate Cirara for $120M

                Biogen Inc. (BIIB) announced the acquisition of Remedy Pharmaceuticals' phase III candidate, Cirara for the treatment of large hemispheric stroke (LHI).

                  AstraZeneca Imfinzi Positive in Phase III Lung Cancer Study

                  AstraZeneca PLC (AZN) recently announced positive data from a phase III PACIFIC study evaluating its oncology candidate, Imfinzi (durvalumab).

                    Nektar Therapeutics (NKTR) Loss Wider Than Expected in Q1

                    Nektar Therapeutics (NKTR) reported first-quarter 2017 loss of 42 cents per share, wider than the Zacks Consensus Estimate of a loss of 40 cents.

                      Celldex (CLDX) Q1 Loss In Line, Revenues Beat, Shares Up

                      Celldex Therapeutics, Inc. (CLDX) posted first-quarter 2017 loss of 28 cents per share, which was in line with the Zacks Consensus Estimate

                        Incyte (INCY) Q1 Loss Narrower than Expected, Revenues Beat

                        Incyte's first-quarter results were encouraging as the company reported a narrower-than-expected loss and surpassed revenue expectations.

                          AVEO Pharmaceuticals (AVEO) Q1 Loss Narrower Than Expected

                          AVEO Pharmaceuticals, Inc. (AVEO) reported a first-quarter 2017 loss of 12 cents per share, narrower than the Zacks Consensus Estimate as well as year-ago loss of 13 cents.

                            Gilead (GILD) Beats on Q1 Earnings, Revenues Miss Estimates

                            Gilead Sciences, Inc.'s (GILD) first-quarter 2017 earnings (including the impact of stock-based compensation expenses) of $2.20 per share beat the Zacks Consensus Estimate of $2.18.

                              Exelixis (EXEL) Posts Earnings in Q1, Cabometyx in Focus

                              Exelixis posted earnings in the first quarter of 2017 while revenues beat estimates driven by Cabometyx.

                                Celldex Therapeutics (CLDX) Q1 Earnings: What's in Store?

                                Celldex Therapeutics, Inc. (CLDX) is expected to report first-quarter 2017 results on May 4. Celldex's performance has been encouraging with a three-quarter average positive surprise of 8.06%.

                                  Drug Stocks Q1 Earnings Slated for May 2: MRK, PFE & GILD

                                  The Q1 earnings season is in full swing with financial results from 288 S&P 500 members or 63.8% of the index already out as of Apr 28, 2017.

                                    Company News for April 28, 2017

                                    Companies in the News are: F,LUV,UNP,BMY

                                      Arpita Dutt headshot

                                      Pharma Stock Roundup: Lilly, Bristol-Myers, Novartis Q1 Earnings & More

                                      Several major pharma companies including Lilly (LLY) and Bristol-Myers reported Q1 results this week.

                                        Bristol-Myers (BMY) Beats on Q1 Earnings, Ups 2017 View

                                        Bristol-Myers Squibb Company's (BMY) first-quarter 2017 earnings of 84 cents per share beat the Zacks Consensus Estimate of 72 cents and surged 14% from the year-ago period.

                                          Pharma Stocks Q1 Earnings Roster for Apr 27: CELG, ABBV, BMY

                                          Celgene, AbbVie and Bristol-Myers Squibb are expected to report earnings on Apr 27.

                                            Exelixis (EXEL) Q1 Earnings: Will the Stock Disappoint?

                                            Exelixis, Inc. (EXEL) is scheduled to report first-quarter 2017 results on May 1, after the market close.

                                              Bristol-Myers (BMY) to Post Q1 Earnings: What's in Store?

                                              Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2017 results on Apr 27, before the opening bell.

                                                Sweta Killa headshot

                                                Is Pain Ahead for Healthcare ETFs After Weak JNJ Q1?

                                                Results from Johnson and Johnson could be a warning sign for other drug makers, which are scheduled to report this week and the next.

                                                  Arpita Dutt headshot

                                                  3 Key Factors to Look Out for in Biogen's Q1 Results

                                                  With Biogen (BIIB) set to report Q1 results tomorrow, here is a look at 3 key factors investors will be focused on apart from earnings and revenue.